跳至主要内容
临床试验/NCT03471507
NCT03471507已完成2 期

Efficacy of a Topical Pain Relief Spray Containing Herbal Oil Extracts (Bonipar) Among Individuals With Acute and Chronic Musculoskeletal Pain

Winston Parris, MD1 个研究点 分布在 1 个国家目标入组 164 人开始时间: 2020年12月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
164
试验地点
1
主要终点
Change in Pain as Measured by Subjective Pain Intensity Rating (SPIR)

研究概览

简要总结

This study is a non-inferiority study comparing efficacy and onset of action between the herbal extracts topical solution, Bonipar, and diclofenac sodium topical solution, diclofenac topical solution 1.5%.

详细描述

This study is a non-inferiority study comparing efficacy and onset of action between the herbal extracts topical solution, Bonipar, and diclofenac sodium topical solution, diclofenac topical solution 1.5% (approved by the FDA as a topical analgesic). Approximately 168 Duke patients will be recruited from Duke Pain Clinic, and selected Duke primary care practices. Individuals who report acute (less than 3 months duration) or chronic musculoskeletal pain of any intensity will be considered for enrollment into the study. After obtaining consent, eligible subjects will be will be randomized to receive Bonipar or diclofenac topical solution 1.5%.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

The bottles will be labelled by pharmacy either "Drug A" or Drug B" according to their designation with a label affixed to cover any drug manufacturing labeling. Only the dispensing pharmacy will not be blinded.

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Bonipar

Experimental

干预措施: Bonipar (Drug)

Diclofenac topical solution 1.5%

Active Comparator

干预措施: Diclofenac sodium topical solution 1.5% (Drug)

结局指标

主要结局

Change in Pain as Measured by Subjective Pain Intensity Rating (SPIR)

时间窗: Baseline (approximately 24 hours before consent) to approximately 1 week post administration of study drug (or comparator)

The SPIR is a patient-reported graduated scale where 0 = no pain and 10 = the maximum pain imaginable.

次要结局

  • Number of Participants Who Experienced Adverse Effects and/or Complications(Up to approximately 1 week)

研究者

发起方
Winston Parris, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Winston Parris, MD

Professor Emeritus

Duke University

研究点 (1)

Loading locations...

相似试验